DesRosier Thomas
Known title: Chief Legal Officer and EVPCIK: 0001435744
Associated companies
Transaction History
| MCRB | ▼ Sell | Open Market | 82 | $373 | 8/17/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 245 | — | 8/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 79 | $595 | 5/18/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 244 | — | 5/15/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 244 | — | 2/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 78 | $661 | 2/15/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 112 | — | 11/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 132 | — | 11/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 76 | $1K | 11/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 76 | $1K | 8/18/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 133 | — | 8/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 111 | — | 8/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 133 | — | 5/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 111 | — | 5/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 79 | $575 | 5/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,300 | $3K | 2/18/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,657 | — | 2/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 8,907 | — | 2/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 878 | $475 | 11/18/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,656 | — | 11/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,259 | $3K | 10/28/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 13,500 | $0 | 10/27/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 873 | $733 | 8/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,656 | — | 8/15/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,656 | — | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 843 | $792 | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 3,939 | $4K | 2/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 10,625 | — | 2/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,156 | $6K | 10/30/2023 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 13,501 | $0 | 10/27/2023 | View on chart |
| MCRB | ▲ Buy | Grant | 63,492 | $200K | 7/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026
Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.